(5-bromopyridin-2-ylmethyl)dimethylamine | 908271-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-bromopyridin-2-ylmethyl)dimethylamine
• 英文别名: [(5-Bromopyridin-2-yl)methyl]dimethylamine；1-(5-bromopyridin-2-yl)-N,N-dimethylmethanamine
• CAS: 908271-69-2
• 化学式: C₈H₁₁BrN₂
• 分子量: 215.093
• InChiKey: HGRJHRRQFVHPLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Nitro-6-pyrimidin-2-yl-4-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-phenylamine 、 (5-bromopyridin-2-ylmethyl)dimethylamine 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy

  摘要：

  A series of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV were identified and optimized to mid-to-low nanomolar potency against a variety of bacteria. However, in spite of seemingly adequate exposure achieved upon IV administration, the in vivo efficacy of the early lead compounds was limited by high levels of binding to serum proteins. To overcome this limitation, targeted serum shift prediction models were generated for each subclass of interest and were applied to the design of prospective analogs. As a result, numerous compounds with comparable antibacterial potency and reduced protein binding were generated. These efforts culminated in the synthesis of compound 10, a potent inhibitor with low serum shift that demonstrated greatly improved in vivo efficacy in two distinct rat infection models. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.022
• 作为产物：
  描述：

  5-溴-2-(溴甲基)吡啶 、 二甲胺 在 水 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 以to give 0.90 g (64%) of the title compound as a brown oil的产率得到(5-bromopyridin-2-ylmethyl)dimethylamine
  参考文献：
  名称：

  IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS

  摘要：

  本发明提供了公式（I）的VEGF-R2抑制剂化合物以及使用这些化合物的方法。

  公开号：

  US20090227622A1

文献信息

• [EN] PYRIDAZINONE-AMIDES DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDAZINONE-AMIDES
  申请人：MERCK PATENT GMBH

  公开号：WO2014121931A1

  公开（公告）日：2014-08-14

  The present invention relates to compounds of formula (I) wherein R1, Ra, Rb and Z have the meaning given in claim 1, and their use in the prophylaxis and treatment of diseases.

  本发明涉及式（I）的化合物，其中R1、Ra、Rb和Z具有权利要求1中给出的含义，并且它们在预防和治疗疾病中的用途。
• PYRIDAZINONE-AMIDES DERIVATIVES
  申请人：MERCK PATENT GMBH

  公开号：US20150376167A1

  公开（公告）日：2015-12-31

  The present invention relates to compounds of formula (I) wherein R1, Ra, Rb and Z have the meaning given in claim 1, and their use in the prophylaxis and treatment of diseases.

  本发明涉及公式（I）中R1、Ra、Rb和Z具有claim1中给定的含义的化合物，以及它们在预防和治疗疾病中的用途。
• NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Edmondson Scott D.

  公开号：US20120225886A1

  公开（公告）日：2012-09-06

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了公式（I）的化合物，其药物组合物，以及使用它们治疗或预防通过激活β3肾上腺素受体介导的疾病的方法。
• Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors
  申请人：Eli Lilly and Company

  公开号：US07666879B2

  公开（公告）日：2010-02-23

  The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.

  本发明提供了公式为(I)的抑制VEGF-R2的化合物以及使用这些化合物的方法。
• [EN] 1,5,7-TRI-SUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES<br/>[FR] DÉRIVÉS D'ISOQUINOLÉINE 1,5,7-TRI-SUBSTITUÉS, LEUR PRÉPARATION ET LEUR UTILISATION DANS DES MÉDICAMENTS<br/>[ZH] 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
  申请人：[en]SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.;[zh]上海海雁医药科技有限公司

  公开号：WO2018086589A1

  公开（公告）日：2018-05-17

  提供了1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途。具体地，提供了式(I)化合物或其药学上可接受的盐、立体异构体、溶剂化物或前药，及其制备方法和应用。